



Exploiting the Extrinsic and the Intrinsic Apoptotic Pathways for Cancer Therapeutics

Louiza Belkacemi*

Department of Biology and Biochemistry, University of Houston, USA

Abstract

Cell death or apoptosis is a cellular process that occurs in physiological and pathological conditions. Cancer is a scenario where there is too little apoptosis. Apoptotic extrinsic and intrinsic signaling pathways are two major mechanisms of apoptosis. Defects can occur at any point along these pathways, leading to malignant transformation and resistance to anti-cancer drugs. The understanding of the extrinsic and intrinsic apoptotic signaling mechanisms has provided the basis for novel targeted therapies that can stimulate death in cancer cells and or sensitize them to established cytotoxic agents and radiation therapy. This review focuses on the current knowledge of the extrinsic and intrinsic pathways to apoptosis in normal and diseased cells and the agents developed to target them.

Keywords: Apoptosis; Cancer therapeutics; Extrinsic pathways; Intrinsic pathways

Introduction

Cancer is a primary cause of death worldwide. The World Health Organization estimates that by 2030 there will be 13 million cancer related deaths [1]. The underlying etiology of cancer was first attributed to accelerated and dysregulated cell proliferation that led to cellular increase and accumulation of tissue mass. Later, it had been found that some cancers were caused by the lack of physiological cell death (also referred to as cellular suicide or apoptosis) rather than an increased rate of cell proliferation [2]. Nowadays, the dysregulation of the two well-defined apoptotic signaling pathways; the extrinsic/death receptors and the intrinsic/mitochondrial pathway, is considered a major clinical problem to overcome in the treatment of cancer.

The notion that apoptosis might impact cancer malignant phenotype dated back to the early 1970s where pathologists observed that radiation and chemotherapy can yield cell death with morphological characteristics of apoptosis [3]. Kerr et al. [4] were the first to raise the possibility that a large percentage of cell loss from tumors was due to apoptosis. Since then, many investigators have ventured into targeting various aspects of apoptosis to trigger tumor cell death and enhance cancer therapies [5,6]. Several target molecules aimed at the two-main apoptotic signaling pathways; the extrinsic pathway and the intrinsic pathway led to the development of various agents including natural and synthetic compounds, antibodies, antisense, and silencing RNA. Specific Histone Deacetylase (HDAC) inhibitors (HDIs) have also emerged as a new target for cancer therapy [7] since HDIs can induce apoptosis via the extrinsic and the intrinsic pathways [8].

This review provides a general overview on how the disruption of normal function of the extrinsic and the intrinsic apoptotic pathways promotes the incidence of cancer and the strategies directed at these pathways in cancer therapeutics.

Mechanisms of apoptosis regulation

Different stresses originated either from outside or inside the cell trigger cell death by apoptosis [9]. As indicated above, to date, there are two major apoptotic pathways: the extrinsic and the intrinsic pathway. These two pathways are tightly linked with some molecules from one pathway able to influence the other pathway [10]. The extrinsic and intrinsic pathway proteins abbreviations and alternate nomenclature are summarized in Table 1 and 2.

The extrinsic apoptotic pathways: The extrinsic apoptotic signaling pathways or death receptor pathways are mediated by transmembrane death receptors, which depend on ligand-receptor interactions for cell death effectors activity [11]. These receptors are part of the Tumor Necrosis Factor (TNF) receptor gene super family. They share cysteine-rich extracellular domains and a cytoplasmic death. The best-characterized ligands and corresponding death receptors are; FasL/Fas

OPEN ACCESS

*Correspondence:

Louiza Belkacemi, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA, E-mail: lbelkacemi1@gmail.com

Received Date: 23 Jul 2018

Accepted Date: 22 Aug 2018

Published Date: 24 Aug 2018

Citation:

Belkacemi L. Exploiting the Extrinsic and the Intrinsic Apoptotic Pathways for Cancer Therapeutics. *J Cancer Cure*. 2018; 1(1): 1004.

Copyright © 2018 Louiza Belkacemi.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1: Extrinsic pathway proteins, abbreviations, and other nomenclature.

Abbreviation	Protein full name	Other Nomenclature
Apo2L	Apo2 ligand	TNFSF10, TRAIL, TNF-related apoptosis inducing ligand
Apo3L	Apo3 ligand	TNFSF12, Apo3 ligand, TWEAK, DR3LG
caspase-8	Cysteiny l aspartic acid-protease 8	FLICE, FADD-like Ice, Mach-1, Mch5
DISC	Death inducing signaling complex	None
DED	Death effector domain	Apoptosis antagonizing transcription factor, CHE1
DR3	Death receptor 3	TNFRSF12, Apo3, WSL-1, TRAMP, LARD, DDR3
DR4	Death receptor 4	TNFRSF10A, TRAILR1, APO2
DR5	Death receptor 5	TNFRS10B, TRAIL-R2, TRICK2, KILLER, ZTNFR9
FADD	Fas-associated death domain	MORT1
Fas	Fatty acid synthetase receptor is a transmembrane receptor of the tumor necrosis factor (TNF) receptor superfamily	Fas receptor, TNFRSF6, APT1, CD95
FasL	Fatty acid synthetase ligand	Fas ligand, TNFSF6, Apo1, apoptosis antigen ligand 1, CD95L, CD178, APT1LG1
c-FLIP	FLICE-inhibitory protein	Casper, I-FLICE, FLAME-1, CASH, CLARP, MRIT
TNF- α	Tumor necrosis factor alpha	TNF ligand, TNFA, cachectin
TNFR1	Tumor necrosis factor receptor 1	TNF receptor, TNFRSF1A, p55 TNFR, CD120a
TRADD	TNF receptor-associated death domain	TNFRSF1A associated via death domain




Figure 1: Mechanisms of cell death from the perspective of death receptor and mitochondrial pathways.
 (1) The main extrinsic pathways to apoptosis include Fas/FasL, TRAIL/D4/D5 and TNF- α /TNFR1 and activation of effector caspases among which caspase-3 leads to excessive programmed cell death.
 (2) The intrinsic pathway is initiated by various signals, essentially extracellular stimuli that activate caspase-8. Caspase-8 converts Bid into truncated Bid that initiates caspase-8 activation. Other BH3-only proteins such as Noxa and Puma engage with anti-apoptotic Bcl-2 family proteins to relieve their inhibition of Bax and Bak to activate them. Next, Bax and Bak are oligomerized and activated, leading to mitochondrial outer membrane permeabilization. Once mitochondrial membrane is permeabilized, cytochrome c and/or Smac/DIABLO is released into the cytoplasm, where they link with an adaptor molecule, apoptosis protease-activating factor 1, and an inactive initiator caspase, procaspase-9, within a multiprotein complex namely the apoptosome. Smac/DIABLO inhibits inhibitors of apoptosis proteins to activate caspase-9 followed by caspase-3 activation that also yields apoptotic cell death.

(also called Apo1 or CD95), TNF- α /TNFR1, Apo3L/DR3 (also called Apo3), Apo2L/DR4 (also called Apo2, TRAILR1, Apo2L/DR5 (also called Apo2, TRAILR2) [12-14]. Among these receptors, FasL/Fas, TNF- α /TNFR1, and TRAIL models are the most studied (Figure 1). The ligation of FasL to the Fasreceptor prompts the binding of the adapter protein FADD. The ligation of TNF- α to TNF results in the binding of the adapter protein TRADD and the recruitment of FADD [15,16]. TRAIL can bind two apoptosis-inducing receptors -TRAIL-R1 (DR4) and TRAIL-R2 (DR5) – and two additional cell-bound receptors incapable of transmitting an apoptotic signal-TRAIL-R3 (LIT, DcR1) and TRAIL-R4 (TRUNDD, DcR2) sometimes called decoy receptors. Finally, a soluble receptor called Osteoprotegerin (OPG) is also

capable of binding TRAIL [17]. The apoptotic signaling pathway of TRAIL is triggered by binding of trimerized TRAIL to DR4 (TRAIL1) and/or DR5 (TRAIL2) [18], followed by receptor clustering leading to the recruitment of FADD as well. In all these models, the FADD protein dimerize with procaspase-8 to form a Death-Inducing Signaling Complex (DISC) known as the primary complex, leading to the activation of procaspase-8 [19] (Figure 1). In Type I cells, activated caspase-8 initiates apoptosis directly by cleaving and thereby stimulating executioner caspases [20]. In Type II cells, caspase-8 must first activate the intrinsic apoptotic pathway (discussed below) to promote cell death [21]. Death receptor-mediated apoptosis can be prevented by cellular FLICE Inhibitory Protein (c-FLIP), which

Table 2: Intrinsic pathway proteins, abbreviations, and other nomenclature.

Abbreviation	Protein full name	Other Nomenclature
14-3-3	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein	14-3-3 eta, theta, zeta, beta, epsilon, sigma, gamma
AIF	Apoptosis Inducing Factor	Programmed cell death protein 8, mitochondrial
Apaf-1	Apoptotic protease activating factor	APAF1
ATF	Activated Transcription factor	None
Bcl-B	Bcl-B selectively binds and suppresses apoptosis induction by Bax, but fails to interact with or negate apoptosis triggered by Bak overexpression. Bcl-B protein contains four Bcl-2 homology (BH) domains (BH1, BH2, BH3, BH4)[167]	None
BAD	BCL2 antagonist of cell death	BCL2 binding protein, BCL2L8, BCL2 binding component 6, BBC6, Bcl-XL/Bcl-2 associated death promoter
BAG	BCL2 associated athanogene	BCL2 associated athanogene
BAK	BCL2 antagonist killer 1	BCL2L7, cell death inhibitor 1
BAX	BCL2 associated X protein	Apoptosis regulator BAX
Bcl-2	B-cell lymphoma protein 2	Apoptosis regulator Bcl-2
Bcl-w	BCL2 like 2 protein	Apoptosis regulator BclW
Bcl-x	BCL2 like 1	BCL2 related protein
Bcl-X _L	BCL2 related protein, long isoform	BCL2L protein, long form of Bcl-x
Bcl-X _S	BCL2 related protein, short isoform	BCL2 related protein, short isoform
BID and tBID	BH3 interacting domain death agonist and truncated BID	p22 BID
BIK	BCL2 interacting killer	NBK, BP4, BIP1, apoptosis inducing NBK
BIM	BCL2 interacting protein BIM	BCL2 like 11
Blk	Bik-like killer protein	B lymphoid tyrosine kinase, p55-BLK, MGC10442
BMF	Bcl2 Modifying factor	None
CAD	Caspase-Activated DNase-9	CAD/CPAN/DFF40
Caspase-9	CysteinyI aspartic acid-protease-9	ICE-LAP6, Mch6, Apaf-3
HtrA2/Omi	High-temperature requirement	Omi stress regulated endoprotease, serine protease Omi protein A2
IAP	Inhibitor of Apoptosis Proteins	XIAP, API3, ILP, HILP, HIAP2, ciAP1, API1, MIHB, NFR2-TRAF signaling complex proteins
ciAP1 and ciAP2	Cellular inhibitor of apoptosis protein-1/2	ciAP1: BIRC2
Mcl-1	Anti- apoptotic Myeloid Cell Leukemia Sequence 1	TM; EAT; MCL1L; MCL1S; Mcl-1; BCL2L3; MCL1-ES; bcl2-L-3; mcl1/EAT
Noxa	Phorbol-12-myristate-13-acetate-induced protein 1	PMA induced protein 1, APR
Puma	Bcl-2 binding component 3	JFY1, PUMA/JFY1, p53 up-regulated modulator of apoptosis
Smac/DIABLO	Second mitochondrial activator of caspases/direct IAP binding protein with low PI	None
XIAP	X-linked inhibitor of apoptosis protein	Inhibitor of apoptosis protein 3 (IAP3), baculoviral IAP repeat-containing protein 4 (BIRC4)

shares sequence homology with caspase-8 and may interfere with the FADD-procaspase-8 interaction. This results in the prevention of caspase activation by competing for FADD binding, and thus, impeding the recruitment of procaspase-8 to the DISC, and its activation [22].

The intrinsic pathway: The intrinsic signaling pathway implicates intracellular signals that are controlled by the mitochondria. This signals yield an alteration of the inner mitochondrial membrane, a loss of the mitochondrial transmembrane potential, and a release of cytochrome c and Smac/DIABLO [23]. After which cytochrome c binds and activates Apaf-1 as well as procaspase-9 to form an apoptosome [24]. Causing caspase-9 activation. Smac/DIABLO can be blocked by Inhibitors Of Apoptosis (IAPs) activity [25,26]. For example, XIAP efficiently blocks the intrinsic as well as extrinsic pathways of apoptosis by binding to upstream caspase-9 and downstream caspases-3 (Figure 1).

The Bcl-2 family of proteins regulate mitochondrial apoptosis

[27,28]. The family consists of more than 20 members with pro- or anti-apoptotic functions. The family is divided into three groups based on the presence of conserved Bcl-2 Homology (BH) regions vital for heterodimeric interactions among its members [29]. The anti-apoptotic proteins Bcl-2, Bcl-XL, Bcl-XS, Bcl-W, and Mcl-1 contain all four BH regions. The pro-apoptotic proteins are divided into two groups according to their number of BH3 and function. The multi-region pro-apoptotic proteins, Bax, Bak, and Bok share BH 1-3 regions, whereas the BH3-only proteins Bad, Bim, Bid, Noxa, Puma, Bik/Blk, and Bmf have homology in the BH3 region only [30]. Additional Bcl-2 family members have been described with potential pro-apoptotic (Bcl-G, Bcl-Rambo) or prosurvival (Bcl-B) capacity [31]. Based on the binding between different Bcl-2 family members, two models of Bax and Bak activation have been put forward; the direct and indirect models [32]. In the direct model, BH3-only proteins such as Bid, Bim, and PUMA (named activators) bind directly to Bax and Bak and Bcl-2/Bax ratio determine the sensitivity of a cell to a wide variety of apoptotic stimuli. In the indirect model, Bax and

Bakarestimulated after being displaced from pro-survival proteins by BH3-only proteins. Notably, aspects of both the direct and indirect models may be important [33]. Apoptosis take place once Bax or Bak generate an apoptotic pore in the mitochondrial outer membrane [34]. The Bax and Bak oligomerization and activation cause mitochondrial pathway activation. Furthermore, Bad heterodimerization with either Bcl-XL or Bcl-2, neutralizes either protective effect and promotes cell death [35]. Notably, the anti-apoptotic Bcl-2 family controls the activation of caspases as well. Proteins such as Bcl-2 and Bcl-XL prevent apoptotic death primarily by regulating the activation of caspase proteases [36]. For instance, Bcl-XL binds to Apaf-1 and inhibits activation of caspase-9 [37] (Figure 1).

The joint pathways: The apoptotic extrinsic and intrinsic pathways are not simply two parallel programs converging on common caspases machinery; a number of 'cross-talk' happens between the two pathways. Caspase-deficient mice demonstrate that the prerequisite for different death effector molecules during apoptosis is highly variable depending on stimuli. For example, receptor-mediated activation of caspase-8 can cleave and activate Bid, [38,39]. Facilitating cytochrome c release from the mitochondria [10]. Numerous studies have reported that the spontaneous membrane binding of tBid causes the migration of soluble Bax and Bcl-XL to the membranes [40,41]. Further, serine phosphorylation of Bad is correlated with 14-3-3, a member of a family of multifunctional phosphoserine binding molecules. Once Bad are phosphorylated, it is segregated by 14-3-3 in the cytosol. When Bad is unphosphorylated, it translocate to the mitochondria and acts to release cytochrome c [42]. Downstream caspases from the extrinsic and the intrinsic pathways stimulate cleavage of protein kinases, cytoskeletal proteins, DNA repair proteins and inhibitory subunits of endonucleases family. They also impact the cytoskeleton, cell cycle and signaling pathways, which altogether contribute to the typical morphological alterations noted in apoptosis [43].

Taken together these data support the cross talk between the two main pathways to apoptosis.

Imbalance in apoptotic main mechanisms results in cancer

As described above, the extrinsic pathway is regulated at different levels that can be disrupted in tumor cells. Particularly, decreased death receptors have been implicated in the evasion of the death signaling pathways in various cancers [44] For instance, Fasreceptor is down regulated in hematomas versus normal hepatocytes, which is likely to reflect its contribution to evasion of the immune system in liver carcinogenesis [45]. The loss of Fas and the dysregulation of FasL, DR4, DR5, and TRAIL indicate a potential functional role of these death ligands and receptors during cervical carcinogenesis [46]. As the inhibiting of Fas and TRAIL signaling involves the downregulation of procaspase-8 by c-FLIP, the over expression of c-FLIP observed in carcinomas supports tumor development and progression. Other studies demonstrating reduced expression of Fas receptor involvement in treatment-resistant leukemia, [47]. And neuroblastoma [48]. Suggested that the down regulation of surface receptor expression likely to represent a mechanism of acquired drug resistance. All together, these data indicate that death receptors downregulation promotes tumor growth progression.

As stated previously, the intrinsic pathway is controlled by interactions between pro- and anti-apoptotic members of the Bcl-2 protein family. A change in the expression of either type of protein

is recurrent in many human cancers. Particularly, increased Bcl-2 protein levels are generally found in many hematopoietic malignancies such as acute and chronic myeloma, [48] and prostate cancer [49]. Overexpression of Bcl-XL confers a multi-drug resistance phenotype to tumor cells and prevents them from undergoing apoptosis [50]. Similarly, mutated or downregulated Bax and Bcl-2 are observed in certain cancers as well. Notably, colorectal cancers with microsatellite instability, mutations in the bax gene are very common. Miquel et al. [51] showed that dysregulated apoptosis post bax (G)8 frame shift mutations could contribute to resistance of colorectal cancer cells to anticancer treatments.

The Inhibitor of Apoptosis Proteins (IAPs) are also important regulators of cell death and cell survival. There are convincing data implicating the IAPs in cancer development [52]. IAPs known as BIRCs (BIR domain containing proteins) are a class of highly conserved proteins characterized by the presence of Baculovirus IAP Repeat (BIR) domain, a Zn²⁺ ion coordinating protein-protein interaction motif [53] largely known for the regulation of caspases. There are eight mammalian IAPs/BIRCs; among which cIAP-1, cIAP-2, Survivin and XIAP, [53] which are the best known for stimulation of cancer cell survival, are over expressed in breast cancer [54]. The role of IAPs in tumorigenesis is dependent of the circumstance and the cell type [55]. For instance, c-IAP2 is over expressed in pancreatic intraepithelial neoplastic lesions and pancreatic ductal adenocarcinomas and is considered an early event in the progression of pancreatic cancer [56]. Survival analysis revealed that patients co-expressing cIAP1/cIAP2 in pancreatic tumors have shorter survival rate vs. cases where only one or none of the proteins was expressed [56]. XIAP over expressed in esophageal cancer tissues perhaps confers resistance to apoptosis induction by activating caspase-3 and promoting tumorigenesis [57]. Survivin is a protein from IAP proteins which is greatly expressed in a variety of cancers but has very low expression in the corresponding normal tissues. Survivin expression is often correlated with tumor metastasis and chemo resistance [57].

Caspases are a family of cysteinyl aspartate-specific proteases that can be broadly classified into two groups: (1) those associated with caspase-1 (e.g. caspase-1, -4, -5, -13, and -14) and generally implicated in inflammatory processes, and (2) those that have a pivotal role in apoptosis (e.g. caspase-2, -3, -6, -7, -8, -9 and -10). The second group is further divided into (i) initiator caspases (e.g. caspase-2, -8, -9 and -10), primarily responsible for the initiation of the apoptotic pathway and (ii) effector caspases (caspase-3, -6 and -7), responsible in the cleavage of cellular elements during apoptotic cell death [58]. As caspases remain one of the important players in the initiation and the execution of apoptosis, it is reasonable to believe that low levels of caspases expression or impairment in caspase function may lead to decreased apoptosis and carcinogenesis. Several reports point out to the important role of caspases in cancer development [7,59]. Activation of caspases is frequently impaired in human cancers, progression and therapy resistance [60]. Tumor progression toward metastatic disease was observed in 16 out of 20 primary melanomas (80%) with elevated amounts of cleaved caspase-3. Conversely, only 10 out of the 37 primary melanomas (20%) with low amounts of cleaved caspase-3 developed metastatic disease [61]. The investigators attribute the difference in tumor metastasis to increased migration and invasion, features that may be associated with non-apoptotic roles of caspases at conditions of sub-lethal activation [62]. Fong et al. [63] observed that in some instances more than one caspase can be downregulated, suggesting that this may contribute to tumor growth

Table 3: Summary of the treatment strategies targeting the extrinsic and the intrinsic pathway molecules discussed in this review.

Protein targeted	Drug names and effects
Agents that target the death receptor family of proteins	<ul style="list-style-type: none"> Agents against Fas/FasL
	-ABT-510 has anti-angiogenic activity
	-Anti-APO-1 and anti-Fas antibodies induce apoptosis in different types of cancer cells by binding to a receptor on the surface of the cells they kill.
	-Histone Deacetylase Inhibitors (HDIs): Apicidin stimulates apoptosis through Fas/FasL expression in human acute promyelocytic leukemia cells.
	<ul style="list-style-type: none"> Agents against TRAIL
	-TRAIL suppresses the growth of colon and breast xenografts without the side effects observed with TNF and FasL.
	-TRAIL combination with standard chemotherapeutic agents resulted in increased apoptosis in mutant KRAS non-small cell lung carcinoma cells and in significant inhibition of tumor growth in a prostate cancer in vivo model.
	-HGS-E
	TR1 human agonistic TRAIL-R1 monoclonal antibody is a potent antitumor agent with favorable pharmacokinetic characteristics on a broad range of human malignancies.
	-TRAIL-R2-specific antibodies and recombinant TRAIL can synergize to kill cancer cells as well.
Agents that target the Bcl-2 family proteins	BH3 mimetics
	-Gossypol is a BH3 mimetics and natural compound that inhibited anti-apoptotic Bcl-2, Bcl-x _L , and Mcl-1 proteins. Levo gossypol (AT-101, Ascenta) tested in patients with small cell lung cancer were disappointing. But, apogossypol (Burnham Institute) seemed to better target Bcl-2 and Mcl-1 and has single-agent activity in Bcl-2-transgenic mice and has better efficacy with less toxicity than gossypol.
	-ABT-737 exhibits cytotoxicity in lymphoma, small cell lung carcinoma cell line and primary patient-derived cells and caused regression of established tumors with a high percentage of cure in mice. This agent inhibits Bcl-2, Bcl-X _L , and Bcl-W proteins and binds the anti-apoptotic Bcl-2 family. It shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. It does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1).
	-GX15-070 (obatoclax, Gemin X) blocks most anti-apoptotic Bcl-2 family of proteins. It has a relatively low affinity for Bcl-2, Bcl-X _L , Bcl-w, and Mcl-1 versus ABT-737. GX15-070 combined with PI3-kinase/mTOR-inhibitor BEZ235 inhibit chronic lymphocytic leukemia cells.
	-A-1210477 is a potent and selective Mcl-1 inhibitor over other Bcl-2 family members.
	-BH3 mimetics e.g. ABT-737, ABT-263, GX15-070, and A-1210477 have entered in clinical trials.
	-HA14-1 inhibits the binding of Bcl-2 and Bcl-X _L to Bax and Bak and induce apoptosis in glioma cells and colon cancer cells.
	- Silencing the Bcl2 anti-apoptotic proteins/genes
	-G3139 (Oblimersen sodium, Genasense, Genta Inc., Berkeley Heights, NJ) silencing resulted in decreased Bcl-2 protein translation.
	-Silencing proto-oncogene Bmi-1 in MCF breast cancer cells downregulated Bcl-2 expression making the cells susceptible to doxorubicin.
	-Antisense Bcl-X _L oligonucleotide and bispecific antisense bcl-2/bcl-xL oligonucleotide simultaneously downregulates Bcl-2 and Bcl-X _L expression, induces apoptosis, and inhibits growth of different tumor types.
	-Doxorubicin loaded into multivalent aptamer-siRNA conjugates containing Bcl2-specific siRNA activated caspase-3/7 and decreased cell viability.
	<ul style="list-style-type: none"> HDAC inhibitors
	-Sodium butyrate downregulates Bcl-X _L protein in mesothelioma cells. It stimulates hepatocellular carcinoma cells into their normal phenotype and upregulate of Bcl-2 and Mcl-1/EAT
	-Depsipeptide decreases the expression of Bcl-2, Bcl-X _L , and Mcl-1 in multiple myeloma cells and activates Bim to initiate apoptosis.
-Fenretinide down-regulates Bcl-2, Bcl-X _L , and Mcl-1 in leukemia	
-Flavopiridol reduces Mcl-1 levels in lung cancer cells.	
IAPs	<ul style="list-style-type: none"> XIAP and cIAPs
	-Birnapant (TL32711), a second-generation bivalent antagonist of both XIAP and cIAP1. Birnapant stabilized the cIAP1-BUCR (BIR3-UBA-CARD-RING) dimer and promoted auto-ubiquitylation of cIAP1 in vitro. Improved analogs were also obtained from the development of bivalent SMAC mimics that targeted more than one BIR domain region on XIAP, increasing the rate of apoptosis.
	-Cyclo-peptidic SMAC mimetics, 2 and 3 are endogenous second mitochondria-derived activators of caspase/direct IAP binding protein (SMAC/DIABLO) protein. Endogenous SMAC/DIABLO binding to BIR domain of XIAP, competitively preventing its binding with effector caspases-9, 3 and 7, thus blocking their inhibition resulting in active caspases.
	-The non-peptidic SM-164, an IAP inhibitor strongly enhances TRAIL activity by concomitantly targeting XIAP and cIAP1.
	<ul style="list-style-type: none"> Survivin
	-Ardisianone, a natural benzoquinone that demonstrated a time-dependent degradation of Survivin in human refractory prostate cancer cell lines. This molecule hinders cell proliferation and induces both caspase-dependent and caspase-independent apoptosis via down-regulation of Bcl-2 proteins.
	-YM-155 suppresses transactivation and expression of Survivin. It effective in in vivo models of prostate, pancreatic, and lung cancer.
	-GDP366 potently and selectively inhibited the expression of Survivin—FL1188 Survivin inhibitor has superior antitumor efficacy in human tumor xenograft models versus to standard anti-cancer drugs.
	-Survivin derived peptides prime CTLs in vivo in murine model of melanoma.
	-Survivin specific CTLs that can lyse Human Leucocyte Antigens (HLA) matched tumor target cells have been observed in cancer patients.
- Dendritic cell vaccines, DNA vaccines peptide vaccines or VLP based vaccine for Survivin have also been assessed in preclinical or clinical investigations.	

	-siRNA approach targeting Survivin diminished radio resistance in pancreatic cancer cells and non-small cell lung cancer cells.
	-siRNA aimed at blocking Survivin-hsp90 connection have also shown anti-cancer effects in androgen independent prostate cancer models.
	-Disrupting BRIC5 expression with lentiviral CRISPR/Cas9 nickase vector significantly reduced cell growth and invasion and induced cell apoptosis in ovarian cancer cells.
Caspases	-Justicidin A stimulates apoptosis in hepatocellular carcinoma through activation of caspase-8,
	-Saussurealappa herbal medicine suggested for anticancer effects in neuroblastoma, lung cancer, hepatocellular carcinoma gastric cancer, and prostate cancer. It suppresses the expression of pro-caspases-8/9/3 and induce apoptosis in prostate cancer cells.
	-Combined natural medicine berberine and evodiamine have synergetic effects against human breast cancer MCF-7 cells in vitro and in vivo induced apoptosis and activate of caspase-7, and caspase-9.
	-Synthetic drugs carbamate and indolone compounds promote Apaf-1 oligomerization and apoptosome formation with activation of caspase-3 and -9.
	-Biotinylated platinum(IV) complexes (1-3) exhibited effective cytotoxicity against the tested cancer cell lines. Complex 1 activated caspase-3.
	-PETCM speed up apoptosome formation by interacting with the inhibitor prothymosin- α .
	-Caspase-1 and caspase-3 replication-deficient adenoviral vectors transduced into prostate tumors decreased tumor growth.
	-Prostate-specific promoter, ARR ₂ PB, drives the expression of inducible caspase 9 in ADV.ARR ₂ PB-iCasp9 adenoviral vector and the expression of inducible caspase-9 yielded in substantial apoptosis in prostate cancer xenografts.
	-5-aza-2' deoxycytidine (decitabine) increases caspase-8 promoter availability, allowing for the binding of SP1 and ETS-like transcription factors. The decitabine-mediated restoration of caspase-8 occurs through genome-wide demethylation which up-regulates the expression of transactivators in brain cancer.
	-Suitable acetylation and transcriptional availability of the caspase-3 promoter, histone deacetylase blockers activated apoptosis and elevated sensitization to TRAIL-, radiation- and chemotherapeutic-stimulated apoptosis in prostate, lung, Ewing's sarcoma and medulloblastoma.
	-HDAC8 knockdown induced apoptotic cell death through caspases activation in oral squamous cell carcinoma.

and development. These investigators found a co-downregulation of both caspase-8 and -10 in a cDNA array hybridization and postulated that it may contribute to the pathogenesis of choriocarcinomas [63].

Collectively, these data show that abnormal changes in the extrinsic and intrinsic signaling pathway proteins promote apoptosis dysfunction and incidence of cancer.

The use of the extrinsic and the intrinsic pathways for cancer therapeutics

The recognition that aberrant apoptosis was a major clinical hurdle to overcome in the treatment of cancer led to the creation of a variety of strategies aimed at exploiting the extrinsic and the intrinsic pathways in cancer therapeutics as discussed in the subsequent sections and in Table 3.

Agents targeting the extrinsic pathways

Death receptors and their ligands specifically, Fas/FasL and Apo2L/TRAIL have extensive anti-tumor activity and subsequently have been pursued as potential targets for cancer therapy [64]. The main agents' characteristics are summarized below.

Agents against Fas/FasL: Several synthetic drugs have been created aiming at increasing Fas pathway cancer therapeutic molecules. One promising synthetic agent is the ABT-510 that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP1, Abbott Laboratories) and competes with it for endothelial cell binding acting as an angiogenesis inhibitor with 1000-fold greater antiangiogenic activity. Similarly to TSP-1, ABT-510 cause's endothelial cell apoptosis via activation of pathways, including Fas/FasL ultimately causing apoptosis [65,66]. Data from a Phase II clinical trial in patients with advanced renal cell carcinoma indicated that ABT-510 slightly improved the toxicity profile of other treatments, but exhibited insufficient clinical activity as a single agent. Therefore, ABT-510 was recommended for the use in combined therapies. Some other drugs that upregulate Fas include doxorubicin in tumor cells [67], 5-fluorouracil (5-FU) in melanoma [68] and colon cancer cells [69], phosphaplatinsin breast cancer cells [70] and ovarian cancer cells [71,72] and cisplatin-resistant cancers [73].

Besides these chemotherapeutic drugs, two monoclonal antibodies, anti-APO-1 and anti-Fas induce apoptosis in different types of cancer cells by binding to a receptor on the surface of the cells they kill [74]. Other drugs such as HDIs not only show selective cytotoxicity against cancer cells, they also enhance the cytotoxic effects of radiation and synergistically stimulate the effects of chemotherapy [75]. HDIs act through the upregulation of the expression of Fas and FasL, cytochrome c release and activation of caspase-9 and caspase-3 [76, 77]. Apicidin is an example of HDI agent that stimulates apoptosis through Fas/FasL expression in human acute promyelocytic leukemia cells [77].

Agents against TRAIL: TRAIL-induced apoptosis is an attractive way to combat cancer because TRAIL takes advantage of the patient's immune cells [17] while it can minimize cytotoxicity to normal, healthy tissue [17]. In fact, exogenous TRAIL was shown to selectively destroy tumor cells without negatively affecting normal cells, making TRAIL and TRAIL-receptor agonists attractive anticancer therapeutics [78,79]. Notably, TRAIL is more efficient in the induction of tumor cell death in combined therapies [80]. For instance, TRAIL acts in synergy with the chemotherapeutic drug 5-Fluorouracil to yield increased apoptosis in mutant V-Ki-ras2 Kirsten rat sarcoma (KRAS) non-small cell lung carcinoma cells [81]. TRAIL suppresses the growth of colon and breast xenografts without the side effects observed with TNF and FasL [78] with synergistic antitumor effects observed when TRAIL was combined with chemotherapy or radiation [82,83]. Similarly, TRAIL tested in combination with agents such as doxorubicin resulted in significant inhibition of tumor growth in a prostate cancer *in vivo* model [84]. Multiple clinically relevant agents upregulate the expression of TRAIL death receptors and cooperate with TRAIL as well as DR4 and DR5-specific agonistic antibodies to exhibit tumor cell death [85]. HGS-ETR1 was the first fully human agonistic TRAIL-R1 monoclonal antibody [86] developed as a specific and potent antitumor agent with favorable pharmacokinetic characteristics. This antibody has the potential to provide therapeutic benefit for a broad range of human malignancies. TRAIL-R2-specific antibodies and recombinant TRAIL can synergize to kill cancer cells as well [87]. It is important to note that the development of TRAIL as

an anticancer drug suffered some setback when Jo et al. [88] reported that human primary hepatocytes were also sensitive to TRAIL-induced apoptosis. Studying *in vitro* normal hepatocytes derived from 20 individuals, the authors observed that in striking contrast with mice and nonhuman primates, >60% of the human hepatocytes underwent apoptosis after exposure to TRAIL [88]. Furthermore, TRAIL was found to induce apoptosis in a human brain cells *in vitro* but in preclinical studies TRAIL failed to induce apoptosis in the brain of laboratory animals [82,83].

Altogether, the promising findings on TRAIL *in vitro* and preclinical studies on animals are limited in their ability to predict toxicity of TRAIL agents in humans. More detailed investigations assessing the different TRAIL drug preparations as a potential cause of toxicity in humans are therefore still required.

Agents targeting the intrinsic pathways.

Inhibitors of the Bcl-2 family

Following the molecular cloning of Bcl-2 by Korsmeyer et al. [89] atonable progress in identifying Bcl-2 family members as targets for cancer drug development has been made with several categories of Bcl-2 family inhibitors created as described in the subsequent sections.

BH3 mimetics: The polyphenol gossypol is a BH3 mimetic derived from the cotton seed plant. It was the first natural compound, which inhibited anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 proteins [90]. In preclinical studies, gossypol has shown potent pro-apoptotic activity [91]. Unfortunately, the results of a Phase II clinical trial using levo gossypol (AT-101, Ascenta), an oral inhibitor of the anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins NOXA and PUMA tested in patients with recurrent chemosensitive extensive-stage small cell lung cancer were unsatisfactory [92]. A gossypol analog, apogossypol (Burnham Institute) seems to better target Bcl-2 and Mcl-1. It also displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol, implying that further development of this agent for cancer therapy may be reasonable [93].

Several synthetic BH3 mimetics such as antagonist ABT-737 [94] exhibits cytotoxicity in lymphoma, small cell lung carcinoma cell line and primary patient-derived cells, and caused regression of established tumors with a high percentage of cure in mice [94] ABT-737 blocks Bcl-2, Bcl-XL, and Bcl-W proteins and binds the anti-apoptotic Bcl-2 family with affinities in the nanomolar magnitude ($K_i \leq 1$ nmol/L for Bcl-2, Bcl-XL, and Bcl-w; $K_i \cong 0.46$ nmol/L for Bcl-B, Mcl-1, Bfl1/A-1). As ABT-737 does not block the pro-survival proteins e.g. Mcl-1, Bcl-B, Bfl-1 (A1); tumors that over express these Bcl-2 family proteins are likely to be resistant to ABT-737. Another Bcl-2 inhibitor, GX15-070 (obatoclox, Gemin X) is a small molecule indole bipyrrrole compound that blocks most anti-apoptotic Bcl-2 family of proteins. Compared with ABT-737, GX15-070 has a relatively low affinity for Bcl-2, Bcl-XL, Bcl-w, and Mcl-1 ($K_i = 220$ nmol/L for Bcl-2 and ~ 0.5 μ mol/L for Bcl-XL, Bcl-w, and Mcl-1 [95]). *In vitro* experiments revealed that GX15-070 produce cooperative growth-inhibitory effects in chronic lymphocytic leukemia cells when combined with PI3-kinase/mTOR-inhibitor BEZ235 [96]. An additional interesting compound is the A-1210477, a potent and selective Mcl-1 inhibitor with K_i and IC_{50} of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members. A-1210477 induces the

hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines. Owing to their potent anti-tumorigenic activity many BH3 mimetics such as ABT-737, ABT-263, obatoclox, and A-1210477 have been developed and entered in clinical trials [97].

In silico screening for compounds that bound the hydrophobic groove of Bcl-2 identified the HA14-1 (Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate) resulted in a small organic compound, [98] which inhibits the binding of Bcl-2 and Bcl-XL to Bax and Bak [99] and induce apoptosis in a wide variety of cancer cells, including glioma cells [99] and colon cancer cells [100]. Notably, the binding affinity of this compound for Bcl-2 is quite high and is significantly higher than affinities of other inhibitors for Bcl-2 [98].

Silencing the Bcl2 anti-apoptotic proteins/genes: Anti-apoptotic Bcl-2 specific siRNA inhibits the expression of target gene *in vitro* and *in vivo* with anti-proliferative and pro-apoptotic effects [101]. The first drug for the Bcl-2 family members that pharmacologically silencing genes coding for Bcl-2 family members was G3139 (Oblimersen sodium, Genasense, Genta Inc., Berkeley Heights, NJ) [102]. This antisense oligonucleotide was designed to specifically bind to the first 6 codons of the human Bcl-2 mRNA sequence to decrease in Bcl-2 protein translation [102]. Unfortunately, this agent did not obtain US Food and Drug Administration approval since it did produce survival differences in a melanoma trial [103]. Wu et al. [104] demonstrated that silencing proto-oncogene Bmi-1 in MCF breast cancer cells downregulated the expression of Bcl-2, rendering these cells more sensitive to doxorubicin as evidenced by an increase in apoptotic cells *in vitro* and *in vivo*. Because Bcl-XL shares high sequence homology regions with Bcl-2, they can be co-expressed in many tumors, but they exhibit different biological roles. Hence, antisense Bcl-XL oligonucleotide and bispecific antisense bcl-2/bcl-xL oligonucleotide, targeting the mRNA homology region of both bcl-2 and bcl-xL, simultaneously down regulates Bcl-2 and Bcl-XL expression, induces apoptosis, and inhibits growth of different tumor types *in vitro* and *in vivo* [105]. Doxorubicin loaded into multivalent aptamer-siRNA conjugates containing Bcl2-specific siRNA exert promising anticancer effects by activating caspase-3/7 and decrease of cell viability, on multidrug-resistant cancer cells due to their high intracellular uptake efficiency [106].

HDAC inhibitors: Several HDIs including sodium butyrate, depsipeptide, fenretinide and flavopiridol can target Bcl2 family in cancer cells. Sodium butyrate downregulates Bcl-XL protein levels by decreasing its RNA expression in mesothelioma cells [107]. This agent can stimulate hepatocellular carcinoma cells into their normal phenotype with an upregulation of anti-apoptotic Bcl-2 and Mcl-1/EAT as well [108]. Similarly, Bak is upregulated by butyrate through increased binding of Sp3 [109]. The depsipeptide is a peptide, which decreases the expression of Bcl-2, Bcl-XL, and Mcl-1 in multiple myeloma cells [110] and activates Bim to initiate apoptosis by Acetylation of FoxO1 [111]. The fenretinide, a synthetic cytotoxic retinoid, down-regulates Bcl-2, Bcl-XL, and Mcl-1 in leukemia cells [112,113]. The flavopiridol, a cyclin-dependent kinase inhibitor, reduces Mcl-1 levels in lung cancer cells [114]. The specificity for the anti-apoptotic Bcl-2 family members for fenretinide, or flavopiridol is lower than for agents that are designed to directly target anti-apoptotic Bcl-2 family members and the ability of such agents to modulate drug resistance mechanisms via the Bcl-2 family proteins

offers opportunities for perhaps synergistic drug.

Collectively, the Bcl-2 family of proteins plays an important role in the response of cancers to both classic chemotherapies and targeted therapies.

Targeting the IAPs

Therapies to target IAPs in cancer has gained substantial scientific interest nowadays. Various drugs that have been developed against IAPs are discussed below.

XIAP and cIAPs: The discovery of SMAC mimetics or IAP antagonists was unveiled following the elucidation of the crystal structure of the interaction between SMAC and IAPs1, 2. SMAC binding to IAPs is facilitated by the interaction of its 4 N-terminal residues (alanine–valine–phenylalanine–isoleucine) with BIR domains on XIAP [115]. Monomeric class of SMAC inhibitors exhibit strong binding affinities with XIAP and cIAP1/2 at nanomolar ranges [116]. These include Birinapant (TL32711), a second-generation bivalent antagonist of both XIAP and cIAP1 with Kd values of 45 nM and <1 nM, respectively (Kd is the equilibrium constant involved in the dissociation of a compound into two or more compounds; the lower the Kd value the higher the affinity of the compound with the IAPs) [117]. A range of assays that evaluated cIAP1 stability and oligomeric state demonstrated that Birinapant stabilized the cIAP1-BUCR (BIR3-UBA-CARD-RING) dimer and promoted auto-ubiquitylation of cIAP1 *in vitro*. This enhanced tolerability has allowed Birinapant to proceed into clinical studies [118]. Improved analogs were also obtained from the development of bivalent SMAC mimics that targeted more than one BIR domain region on XIAP, increasing the rate of cell death by apoptosis [119]. Other IAP antagonists consist of peptidic and non-peptidic small molecules. Two cyclo-peptidic SMAC mimetics, 2 and 3 are endogenous second mitochondria-derived activators of caspase/direct IAP binding protein (SMAC/DIABLO) protein [23,120]. Endogenous SMAC/DIABLO exerts its inhibitory effect on IAPs by binding to BIR domain of XIAP, [115] competitively preventing its binding with effector caspases-9, 3 and 7, resulting in active caspases. The non-peptide SM-164, an IAP inhibitor strongly enhances TRAIL activity by concomitantly targeting XIAP and cIAP1 [121].

The finding that many cancer cell lines and tumors have increased IAP gene copy number, upregulated IAP protein levels, or translocation of specific IAP genes reinforced the premise that deregulated IAP activity might result in tumor initiation, progression, and/or resistance to anticancer treatment through aberrant caspase inhibition [122, 123]. Consistent with this hypothesis, selective elimination of XIAP by genetic depletion or Silencing RNA (siRNA) treatment would make tumor cells sensitive to a variety of conventional chemotherapeutic drugs. Indeed, using antisense strategies and siRNA XIAP molecules resulted in an improved *in vivo* tumor control by radiotherapy [124]. Ohnishi et al. [125] reported that siRNA targeting of XIAP increased radiation sensitivity of human cancer cells. Also, when used together with anticancer drugs, XIAP antisense oligonucleotide exhibit enhanced chemotherapeutic activity in lung cancer cells *in vitro* and *in vivo* [124]. Yamaguchi et al. [126] showed that targeting XIAP by siRNAs sensitize hepatoma cells to death receptor- and chemotherapeutic agent-induced cell death.

Survivin: Survivin protein is encoded by BIRC5 gene. Various strategies have been envisioned to block the expression or the function of Survivin in tumor cells. Small inhibitors targeting the

function of Survivin include Ardisianone, a natural benzoquinone that demonstrated a time-dependent degradation of Survivin in human refractory PC-3 and DU-145 prostate cancer cell lines [127]. This molecule hinders cell proliferation and induces both caspase-dependent and caspase-independent apoptosis via down-regulation of Bcl-2 proteins that produces reactive oxygen species, and disturbs the mitochondrial membrane potential [127]. YM-155 suppresses transactivation of Survivin through direct binding to its promoter [128] and selectively preventing its expression. Survivin has also been shown to be effective *in vivo* models of prostate, pancreatic, and lung cancer [128-130]. GDP366 potently and selectively inhibited the expression of Survivin [131]. Another small molecule Survivin inhibitor FL118 exhibited superior antitumor efficacy in human tumor xenografts models in comparison to standard anti-cancer drugs [131].

Various strategies for therapeutic cancer vaccines have revealed good immunogenicity in clinical trials, still clinical translation of antigen specific cancer vaccines has not been as successful as passive immunotherapy [132]. The rationale for cancer vaccine is to focus a specific tumor antigen as vaccine candidate, create robust antigen presentation mostly through Dendritic Cells (DC), and induce Cytotoxic T Cell (CTL) response. Tumor antigens are made into peptides, inserted onto Major Histocompatibility Complex (MHC) molecules. The MHC-peptide complex is then presented by Antigen Presenting Cells (APCs) to T cells for stimulation. Survivin protein promoted CTL response *in vitro* when presented by DC [133]. Survivin derived peptides prime CTLs *in vivo* in murine model of melanoma [134]. Survivin-specific CTLs that can lyse Human Leucocyte Antigens (HLA) matched tumor target cells have been observed in cancer patients [135]. Various vaccine approaches including DC vaccines, DNA vaccines [136], peptide vaccines or VLP based vaccine for Survivin have also been assessed in preclinical or clinical investigations. These immunotherapeutic approaches targeting Survivin are detailed in Garg et al. [132].

Nucleic acid based strategies, which interfere with Survivin gene expression using antisense Survivin transfected into malignant melanoma cells resulted in spontaneous cell apoptosis [137] and sensitized the cells to chemotherapy [138]. siRNA approach targeting Survivin diminished radio resistance in pancreatic cancer cells [139] and non-small cell lung cancer cells [140]. Moreover, it inhibited proliferation and induced apoptosis in human lung adenocarcinoma [141] and ovarian cancer cells [142]. siRNA aimed at blocking Survivin-Hsp90 connection have also shown anti-cancer effects in androgen independent prostate cancer models [143]. Disrupting BRIC5 expression using the lentiviral CRISPR/Cas9 nickase vector significantly reduced cell growth and invasion and induced cell apoptosis in ovarian cancer cells [144].

In sum, various therapeutics strategies targeting of Survivin have entered a number of clinical trials, including vaccination, inhibitors of transcription and immunotherapy reflect on the importance of Survivin in cancer therapy [145,146]. Targeting common proteins of the extrinsic and intrinsic pathways.

Caspase targeting compounds: The natural drug Justicidin A is derived from the plant *Justicia procumbens*, a traditional herbal remedy for the treatment of cancer [147]. Justicidin A stimulates apoptosis in hepatocellular carcinoma via the activation of both intrinsic and extrinsic apoptosis pathways [147]. Through activation of caspase-8, Justicidin A increases intracellular Bid leading to the

release of cytochrome c; but decreases Bcl-XL. Mitochondrial release of Smac/DIABLO activates caspases-9 and -3 to induce the intrinsic pathway. Saussurea lappa is another traditional herbal medicine suggested for anticancer effects in neuroblastoma [148], lung cancer, [149] hepatocellular carcinoma [150], gastric cancer [151], and prostate cancer [152]. Additionally, Saussurealappa ethanol extract suppresses the expression of pro-caspases-8/9/3 and induce apoptosis in prostate cancer cell [153]. The synergistic effects of combined natural medicine Berberine and Evodiamine against human breast cancer MCF-7 cells *in vitro* and *in vivo* induced apoptosis paralleled by increased expression levels of Bax, reduced expression levels of Bcl-2, and activation of caspase-7, and caspase-9 [154].

Synthetic drugs associated with caspase activation include carbamate and indolone compounds [154]. They promote Apaf-1 oligomerization and apoptosome formation with the ensuing activation of caspase-3 and -9 [155]. Biotinylated platinum (IV) complexes (1-3) exhibited effective cytotoxicity against the tested cancer cell lines, especially complex 1, which was 2.0-9.6 -fold more potent than cisplatin. The complex 1 activates the expression of Bax, and induced cytochrome c release from the mitochondria, and finally activated caspase-3 [156]. Other potential drugs for selective induction of apoptosis were detected using high-throughput screening of the compounds activating caspase-3 as a vital suicide caspase. Among them PETCM [α -(trichloromethyl)-4-pyridine ethanol [157] uses various pathways; e.g., PETCM speed up apoptosome formation by interacting with the inhibitor prothymosin- α [157].

Caspase-based gene therapy has also been used in several studies. Caspase-1 and caspase- 3 replication-deficient adenoviral vectors transducer into prostate tumors showed focal substantial apoptosis free of cytotoxic damage to surrounding tissue and decrease tumor growth [158]. Xie et al. [159] used a prostate-specific promoter, ARR2PB, to drive the expression of inducible caspase 9 in ADV. ARR2PB-iCasp9 adenoviral vector. This promoter has two androgen response regions located upstream of the rat probasin promoter. High levels of intra-prostatic androgens drive the expression of inducible caspase-9 yielded in substantial apoptosis in prostate cancer xenografts [159].

Functional loss of caspase-8 by hypermethylation has been associated with therapeutic resistance of the death-receptor ligands TNF α , TRAIL and Fas [160]. Hence, it was hypothesized that targeting caspase-8 expression may lead to a significant therapeutic effect, especially in tumors experiencing a gene dosage effect or hypermethylation of caspase-8 promoters. In this vein, 5-aza-2'-deoxycytidine (decitabine), a cytosine nucleoside analog, which supports demethylation by preventing DNA methyltransferase covalent binding, increases caspase-8 promoter availability, allowing for the binding of SP1 and ETS-like transcription factors [161]. The decitabine-mediated restoration of caspase-8 occurs through genome-wide demethylation which up-regulates the expression of transactivators [162] in brain cancer [163]. Suitable Acetylation and transcriptional availability of the caspase-3 promoter, histone deacetylase blockers activate apoptosis and elevate sensitization to TRAIL-, radiation- and chemotherapeutic-stimulated apoptosis in prostate, lung, Ewing's sarcoma and medulloblastoma [164-166]. Additionally, HDAC8 knockdown induced apoptotic cell death through caspases activation in Oral Squamous Cell Carcinoma (OSCC) [167] could become a novel therapeutic strategy for OSCC. These data indicate that HDIs may provide an effective mean for the

therapeutic manipulation of caspases as well.

Conclusion

The extrinsic and the intrinsic apoptotic signaling pathways are pivotal for the normal function of apoptosis in humans. More importantly, they have a crucial role in the development and the progression of carcinogenesis. Understanding of the molecular knowledge acquired on these apoptotic signaling pathways in tumors, resulted in designed anticancer strategies and novel therapeutic avenues as highlighted in this review. Some of these discoveries are in preclinical while others have already entered clinical trials. A search at <http://www.clinicaltrials.gov> (a registry and results database of federally and privately supported clinical trials conducted in the United States and around the world) returns a wealth of information. Some of the new agents or treatment strategies have been integrated into combination therapy associated with conventional anticancer drugs in several clinical trials to enhance currently available treatment modalities. Whether these treatment strategies can induce resistance in diverse tumors in the long run, and if they will kill normal cells in overwhelming numbers require immediate further investigations.

References

1. He X, Cheng R, Benyajati S, Ma JX. PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases. *Clin Sci (Lond)*. 2015;128(11):805-23.
2. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. *Acta Oncol*. 2009;48(6):811-21.
3. Doonan F, Cotter TG. Morphological assessment of apoptosis. *Methods*. 2008;44(3):200-4.
4. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer*. 1972;26(4):239-57.
5. Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton C, et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. *Invest New Drugs*. 2008;26(2):139-49.
6. Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-kappaB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. *Int J Oncol*. 2011;38(6):1683-94.
7. Ahn MY, Yoon JH. Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. *Oncol Rep*. 2017;37(1):540-6.
8. Matthews GM, Newbold A, Johnstone RW. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. *Adv Cancer Res* 2012;116:165-97.
9. Bender T, Martinou JC. Where killers meet--permeabilization of the outer mitochondrial membrane during apoptosis. *Cold Spring Harb Perspect Biol*. 2013;5(1):a011106.
10. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer* 2002, 2(4):277-88.
11. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 2007;35(4):495-516.
12. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. *J Biol Chem*. 1997;272(51):32401-10.
13. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. *Science*. 1998;281(5381):1305-8.

14. Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. *Blood*. 2005;106(9):3214-22.
15. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. *Cell* 1995;81(4):495-504.
16. Wajant H. The Fas signaling pathway: more than a paradigm. *Science*. 2002;296(5573):1635-6.
17. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. *Immunology*. 2009;127(2):145-54.
18. Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, Moshkovskii SA, et al. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. *Apoptosis*. 2009;14(6):778-87.
19. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *EMBO J*. 1995;14(22):5579-88.
20. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. *Cold Spring Harb Perspect Biol*. 2013;5(4):a008656.
21. Samraj AK, Keil E, Ueffing N, Schulze-Osthoff K, Schmitz I. Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis. *J Biol Chem*. 2006;281(40):29652-9.
22. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. *Nature*. 1997;386(6624):517-21.
23. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell*. 2000;102(1):33-42.
24. Hill MM, Adrain C, Duriez PJ, Creagh EM, Martin SJ. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. *EMBO J*. 2004;23(10):2134-45.
25. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. *Cancer Res*. 2004;64(20):7183-90.
26. van Loo G, van Gurp M, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES, et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. *Cell Death Differ*. 2002;9(1):20-6.
27. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. *Nat Rev Cancer*. 2002, 2(9):647-56.
28. Hardwick JM, Soane L. Multiple functions of BCL-2 family proteins. *Cold Spring Harb Perspect Biol*. 2013;5(2).
29. Danial NN, Korsmeyer SJ. Cell death: critical control points. *Cell*. 2004;116(2):205-19.
30. Shamas-Din A, Brahmabhatt H, Leber B, Andrews DW. BH3-only proteins: Orchestrators of apoptosis. *Biochim Biophys Acta*. 2011;1813(4):508-20.
31. Westphal D, Dewson G, Czabotar PE, Kluck RM. Molecular biology of Bax and Bak activation and action. *Biochim Biophys Acta*. 2011;1813(4):521-31.
32. O'Neill JW, Manion MK, Maguire B, Hockenbery DM. BCL-XL dimerization by three-dimensional domain swapping. *J Mol Biol*. 2006;356(2):367-81.
33. Dewson G, Kluck RM. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. *J Cell Sci*. 2009;122(Pt 16):2801-8.
34. Vela L, Gonzalo O, Naval J, Marzo I. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. *J Biol Chem*. 2013;288(7):4935-46.
35. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. *Cell*. 1995;80(2):285-91.
36. Newmeyer DD, Bossy-Wetzel E, Kluck RM, Wolf BB, Beere HM, Green DR. Bcl-xL does not inhibit the function of Apaf-1. *Cell Death Differ*. 2000;7(4):402-7.
37. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. *Proc Natl Acad Sci U S A*. 1998;95(8):4386-91.
38. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell*. 1998;94(4):491-501.
39. Esposti MD. The roles of Bid. *Apoptosis* 2002, 7(5):433-440.
40. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneider R, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. *Cell*. 2002;111(3):331-42.
41. Billen LP, Kokoski CL, Lovell JF, Leber B, Andrews DW. Bcl-XL inhibits membrane permeabilization by competing with Bax. *PLoS Biol*. 2008;6(6):e147.
42. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). *Cell*. 1996;87(4):619-28.
43. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. *CA Cancer J Clin* 2005;55(3):178-94.
44. Fulda S. Evasion of apoptosis as a cellular stress response in cancer. *Int J Cell Biol*. 2010;370835.
45. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, et al: The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? *Hepatology*. 1999;30(2):413-21.
46. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. *Gynecol Oncol*. 2005; 96(3):705-13.
47. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. *Leukemia*. 1999;13(11):1854-8.
48. Fulda S, Los M, Friesen C, Debatin KM. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. *Int J Cancer*. 1998;76(1):105-14.
49. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. *Cancer Res*. 1995;55(19):4438-45.
50. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. *Blood*. 1995;86(5):1903-10.
51. Miquel C, Borrini F, Grandjouan S, Auperin A, Viguier J, Velasco V, et al. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. *Am J Clin Pathol*. 2005;123(4):562-70.
52. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. *Oncogene*. 2008;27(48):6252-75.
53. Oberoi-Khanuja TK, Murali A, Rajalingam K. IAPs on the move: role of inhibitors of apoptosis proteins in cell migration. *Cell Death Dis* 2013;4(9):e784.
54. Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, et al. Down-regulation of inhibitor of apoptosis proteins by deguelin selectively

- induces apoptosis in breast cancer cells. *Mol Pharmacol.* 2007;71(1):101-11.
55. Drosopoulos K, Pintzas A. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. *Expert Opin Ther Targets.* 2007;11(5):641-59.
 56. Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. *J Clin Pathol.* 2007;60(8):885-95.
 57. Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, et al. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. *Cancer Biol Ther* 2007, 6(6):973-980.
 58. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. *Infect Immun.* 2005;73(4):1907-16.
 59. Olsson M, Zhivotovsky B. Caspases and cancer. *Cell Death Differ.* 2011;18(9):1441-9.
 60. Fulda S. Therapeutic opportunities based on caspase modulation. *Semin Cell Dev Biol.* 2017.
 61. Liu YR, Sun B, Zhao XL, Gu Q, Liu ZY, Dong XY, et al. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. *Melanoma Res.* 2013;23(4):243-53.
 62. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandennebeele P. Caspases in cell survival, proliferation and differentiation. *Cell Death Differ.* 2007;14(1):44-55.
 63. Fong PY, Xue WC, Ngan HY, Chiu PM, Chan KY, Tsao SW, Cheung AN. Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. *J Clin Pathol.* 2006;59(2):179-83.
 64. Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. *Expert Opin Ther Targets.* 2012;16(1):85-101.
 65. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. *Nat Med.* 2000;6(1):41-8.
 66. Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S, et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. *Cell Death Differ.* 2005;12(6):649-58.
 67. Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo. *Int Immunopharmacol.* 2005;5(2):281-8.
 68. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. *J Immunol.* 2004; 172(7):4599-608.
 69. Zhu Q, Liu JY, Yang CM, Xu HW, Zhang AZ, Cui Y, et al. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. *Eur J Gastroenterol Hepatol.* 2006;18(10):1071-7.
 70. Belkacemi L, Atkins JL, Yang LU, Gadgil P, Sater AK, Chow DS, et al. Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly via an Up-regulation of PEDF in Breast Cancer. *Anticancer Res.* 2018, 38(2):623-46.
 71. Bose RN, Moghaddas S, Belkacemi L, Tripathi S, Adams NR, Majmudar P, et al. Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications To Treat Resistant Cancers. *J Med Chem.* 2015;58(21):8387-401.
 72. Maurmann L, Belkacemi L, Adams NR, Majmudar PM, Moghaddas S, Bose RN. A novel cisplatin mediated apoptosis pathway is associated with acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer. *Apoptosis.* 2015;20(7):960-74.
 73. Yang L, Moghaddas S, Dezvareh H, Belkacemi L, Bark SJ, Bose RN, et al. Insights into the anti-angiogenic properties of phosphaplatins. *J Inorg Biochem.* 2016;164:5-16.
 74. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. *J Exp Med.* 1989;169(5):1747-56.
 75. Ray MR, Jablons D, He B. Lung cancer therapeutics that target signaling pathways: an update. *Expert Rev Respir Med.* 2010;4(5):631-645.
 76. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. *Cancer Res.* 1999;59(17):4392-9.
 77. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. *J Biol Chem* 2002, 277(3):2073-2080.
 78. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumorcidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *Nat Med.* 1999;5(2):157-63.
 79. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. *J Clin Invest.* 1999;104(2):155-62.
 80. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. *Mol Cancer Ther.* 2012;11(1):3-13.
 81. Wang H, Yang T, Wu X. 5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis. *Mol Oncol.* 2015;9(9):1815-24.
 82. Tolcher AW. Regulators of apoptosis as anticancer targets. *Hematol Oncol Clin North Am.* 2002;16(5):1255-67.
 83. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. *Clin Cancer Res.* 2002;8(7):2024-34.
 84. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. *BMC Cancer.* 2005;5:2.
 85. Huang Y, Sheikh MS. TRAIL death receptors and cancer therapeutics. *Toxicol Appl Pharmacol.* 2007;224(3):284-9.
 86. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETRI, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. *Br J Cancer.* 2005;92(8):1430-41.
 87. Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. *Oncogene.* 2015;34(16):2138-44.
 88. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. *Nat Med.* 2000;6(5):564-7.
 89. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. *Semin Cancer Biol.* 1993;4(6):327-32.
 90. Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. *Mol Cancer Ther.* 2009;8(4):904-13.
 91. Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. *Biochem Pharmacol.* 2003;66(1):93-103.

92. Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. *J Thorac Oncol* 2011;6(10):1757-60.
93. Kitada S, Kress CL, Krajewska M, Jia L, Pellicchia M, Reed JC. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). *Blood*. 2008;111(6):3211-9.
94. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. *Cancer Cell*. 2007;12(2):171-85.
95. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. *Proc Natl Acad Sci U S A*. 2007;104(49):19512-7.
96. Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, et al. The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. *Oncotarget*. 2017;8(40):67709-22.
97. Shukla S, Saxena S, Singh BK, Kakkar P. BH3-only protein BIM: An emerging target in chemotherapy. *Eur J Cell Biol*. 2017;96(8):728-38.
98. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. *Proc Natl Acad Sci U S A*. 2000;97(13):7124-9.
99. Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. *Cancer Res*. 2006;66(5):2757-64.
100. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. *Clin Cancer Res*. 2004;10(24):8284-92.
101. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, et al. bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. *J Cell Mol Med*. 2007;11(2):349-61.
102. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. *Antisense Nucleic Acid Drug Dev*. 2002;12(3):193-213.
103. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. *Drugs R D*. 2007;8(5):321-334.
104. Wu X, Liu X, Sengupta J, Bu Y, Yi F, Wang C, et al. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. *Indian J Exp Biol*. 2011;49(2):105-12.
105. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. *Clin Cancer Res*. 2000;6(6):2547-55.
106. Jeong H, Lee SH, Hwang Y, Yoo H, Jung H, Kim SH, et al. Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells. *Macromol Biosci*. 2017;17(4).
107. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. *Am J Respir Cell Mol Biol*. 2001;25(5):562-8.
108. Wakabayashi K, Saito H, Kaneko F, Nakamoto N, Tada S, Hibi T. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. *Int J Oncol*. 2005;26(1):233-9.
109. Chirakkal H, Leech SH, Brookes KE, Prais AL, Waby JS, Corfe BM. Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. *Oncogene*. 2006;25(54):7192-200.
110. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. *Br J Haematol*. 2004;125(2):156-61.
111. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. *Mol Cell*. 2004;13(5):627-38.
112. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregulated bcl-2. *Blood*. 1995;85(2):359-67.
113. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. *J Natl Cancer Inst*. 2008;100(8):580-595.
114. Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Gimenez MS, et al. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. *Mol Cancer Ther*. 2007;6(2):692-702.
115. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature*. 2000;406(6798):855-62.
116. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. *J Med Chem*. 2011;54(8):2714-26.
117. Perimenis P, Galaris A, Voulgari A, Prassa M, Pintzas A. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. *BMC Cancer*. 2016;16:624.
118. Condon SM, Mitsuchi Y, Deng Y, LaPorte MG, Ripplin SR, Haimowitz T, et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. *J Med Chem*. 2014;57(9):3666-77.
119. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. *Cancer Res*. 2008;68(22):9384-93.
120. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. *J Biol Chem*. 2003;278(25):23130-40.
121. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. *Mol Cancer Ther*. 2011;10(5):902-14.
122. Jager R, Zwacka RM. The enigmatic roles of caspases in tumor development. *Cancers (Basel)*. 2010;2(4):1952-79.
123. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. *Nat Rev Drug Discov*. 2012;11(2):109-24.
124. Cao C, Mu Y, Hallahan DE, Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. *Oncogene*. 2004;23(42):7047-52.
125. Ohnishi K, Scuric Z, Schiestl RH, Okamoto N, Takahashi A, Ohnishi T. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. *Radiat Res*. 2006;166(3):454-62.
126. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, et al. Targeting of X-linked inhibitor of apoptosis protein or survivin by

- short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. *Oncol Rep.* 2005;14(5):1311-6.
127. Yu CC, Wu PJ, Hsu JL, Ho YF, Hsu LC, Chang YJ, et al. Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation. *Prostate* 2013;73(2):133-45.
128. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. *Cancer Res.* 2007;67(17):8014-21.
129. Na YS, Yang SJ, Kim SM, Jung KA, Moon JH, Shin JS, et al. YM155 induces EGFR suppression in pancreatic cancer cells. *PLoS One.* 2012;7(6):e38625.
130. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. *J Clin Oncol.* 2009;27(27):4481-6.
131. Shi X, Wang D, Ding K, Lu Z, Jin Y, Zhang J, Pan J. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. *Cancer Biol Ther.* 2010;9(8):640-50.
132. Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. *Cancer Cell Int.* 2016;16:49.
133. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. *Cancer Res.* 2000;60(17):4845-9.
134. Hofmann UB, Voigt H, Andersen MH, Straten PT, Becker JC, Eggert AO. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. *Eur J Immunol.* 2009;39(5):1419-24.
135. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. *Cancer Res.* 2001;61(3):869-72.
136. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. *Vaccine.* 2007; 25(46):7955-61.
137. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. *J Invest Dermatol.* 1999;113(6):1076-81.
138. Sharma H, Sen S, Lo Muzio L, Mariggio A, Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. *Cancer Biol Ther.* 2005;4(7):720-7.
139. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. *Surgery.* 2005;138(2):299-305.
140. Yang CT, Li JM, Weng HH, Li YC, Chen HC, Chen MF. Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells. *Cancer Gene Ther.* 2010;17(2):120-30.
141. Liu Q, Dong C, Li L, Sun J, Li C, Li L. [Inhibitory effects of the survivin siRNA transfection on human lung adenocarcinoma cells SPCA1 and SH77]. *Zhongguo Fei Ai Za Zhi.* 2011;14(1):18-22.
142. Zhang X, Li N, Wang YH, Huang Y, Xu NZ, Wu LY. [Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP]. *Zhonghua Zhong Liu Za Zhi.* 2009;31(3):174-7.
143. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. *Mol Cancer Ther.* 2006;5(1):179-86.
144. Zhao G, Wang Q, Gu Q, Qiang W, Wei JJ, Dong P, et al. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. *Oncotarget.* 2017;8(55):94666-80.
145. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. *Nat Rev Cancer.* 2008;8(1):61-70.
146. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. *Curr Oncol Rep.* 2012;14(2):120-8.
147. Fukamiya N, Lee KH. Antitumor agents, 81. Justicidin-A and diphyllin, two cytotoxic principles from *Justicia procumbens*. *J Nat Prod.* 1986;49(2):348-50.
148. Tabata K, Nishimura Y, Takeda T, Kurita M, Uchiyama T, Suzuki T. Sesquiterpene lactones derived from *Saussurea lappa* induce apoptosis and inhibit invasion and migration in neuroblastoma cells. *J Pharmacol Sci.* 2015;127(4):397-403.
149. Hung JY, Hsu YL, Ni WC, Tsai YM, Yang CJ, Kuo PL, et al. Oxidative and endoplasmic reticulum stress signaling are involved in dehydrocostuslactone-mediated apoptosis in human non-small cell lung cancer cells. *Lung Cancer.* 2010;68(3):355-65.
150. Hsu YL, Wu LY, Kuo PL. Dehydrocostuslactone, a medicinal plant-derived sesquiterpene lactone, induces apoptosis coupled to endoplasmic reticulum stress in liver cancer cells. *J Pharmacol Exp Ther.* 2009;329(2):808-19.
151. Ko SG, Kim HP, Jin DH, Bae HS, Kim SH, Park CH, et al. *Saussurea lappa* induces G2-growth arrest and apoptosis in AGS gastric cancer cells. *Cancer Lett.* 2005;220(1):11-19.
152. Kim EJ, Lim SS, Park SY, Shin HK, Kim JS, Park JH. Apoptosis of DU145 human prostate cancer cells induced by dehydrocostus lactone isolated from the root of *Saussurea lappa*. *Food Chem Toxicol.* 2008;46(12):3651-8.
153. Tian X, Song HS, Cho YM, Park B, Song YJ, Jang S, et al. Anticancer effect of *Saussurea lappa* extract via dual control of apoptosis and autophagy in prostate cancer cells. *Medicine (Baltimore).* 2017;96(30):e7606.
154. Du J, Sun Y, Lu YY, Lau E, Zhao M, Zhou QM, et al. Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis. *Anticancer Res* 2017, 37(11):6141-6151.
155. Nguyen JT, Wells JA. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. *Proc Natl Acad Sci U S A.* 2003;100(13):7533-8.
156. Zhao J, Hua W, Xu G, Gou S. Biotinylated platinum(IV) complexes designed to target cancer cells. *J Inorg Biochem* 2017, 176:175-180.
157. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, et al. Distinctive roles of PHAP proteins and prothymosin- α in a death regulatory pathway. *Science.* 2003;299(5604):223-6.
158. Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, et al. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. *Cancer Res.* 2001; 61(6):2562-71.
159. Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. *Cancer Res.* 2001;61(18):6795-804.
160. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. *Oncogene.* 2001;20(41):5865-77.
161. Liedtke C, Zschemisch NH, Cohrs A, Roskams T, Borlak J, Manns MP, et

- al. Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. *Gastroenterology*. 2005;129(5):1602-15.
162. Banelli B, Casciano I, Croce M, Di Vinci A, Gelvi I, Pagnan G, et al. Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. *Nat Med*. 2002;8(12):1333-1335.
163. Geiger K, Hagenbuchner J, Rupp M, Fiegl H, Sergi C, Meister B, et al. FOXP3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma. *Mol Biol Cell* 2012, 23(11):2226-2234.
164. Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Muller C, Beck JF. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. *Cancer Lett*. 2006;232(2):148-60.
165. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. *Int J Oncol*. 2006;28(3):755-66.
166. Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. *J Cancer Res Clin Oncol*. 2007;133(11):847-58.
167. Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. *J Biol Chem*. 2001;276(16):12481-4.